News

Sarcoidosis Patients Seen to Altered Metabolites and Gut Microbiota in Study

Sarcoidosis patients appear to have unusual energy production and transmethylation of proteins, as well as an abnormal gut microbiota, according to researchers at Wayne State University School of Medicine and colleagues, who compared the metabolites found in sarcoidosis patients with those of healthy people. The study, “Metabolomics connects aberrant bioenergetic, transmethylation,…

Mycobacterium Tuberculosis Linked to Sarcoidosis, a Statistical Study Shows

The study “Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis,” published recently in PLOS One, links some patients with sarcoidosis to the development of the disease and the presence of mycobacterium tuberculosis, which causes tuberculosis. Mycobacterium tuberculosis is the second leading cause of death by infectious disease, preceded only…

In Rare Cases, Sarcoidosis Patients May Develop Psoriasis-like Plaques in Existing Lesions, Report Shows

Psoriasiform lesions are a rare but established manifestation of sarcoidosis, in which psoriasis plaques are formed within sarcoidosis skin lesions. In a recent study, researchers at Thomas Jefferson University in Philadelphia and the University of Miami in Florida presented a case report of a patient with psoriasiform sarcoidosis, and discussed the…

Relief Therapeutics to Acquire FirstString, Move Sarcoidosis and Diabetes Therapies into Phase 3 Trials

Relief Therapeutics, readying for a pivotal clinical trial of a sarcoidosis treatment, announced that it is acquiring FirstString Research in an all-stock transaction that will add an advanced clinical stage product, Granexin, a potential treatment for diabetic foot ulcers and venous leg ulcers, to its drug portfolio. Relief will  also acquire FirstString’s pipeline…